FibroGen (NASDAQ: FGEN), a California biopharmaceutical firm, experienced an unprecedented 21.97% drop over just 10 trading sessions – well below their 52-week high of $100.69 and underscoring its current struggle on Wall Street.
Performance Indicators and Financial Strains
Notably, FibroGen currently boasts an earnings per share (EPS) figure of $2.84; however, their return on equity (ROE) over the last twelve months reveals more concerning trends; being negative at -411.933% indicates significant financial strain as this number indicates net losses relative to shareholder equity.
Intraday Variation
FibroGen reports a weekly and monthly intraday variation average in negative territory over the last seven days and month – 2.18% and 1.85%, respectively.
Revenue Growth Decline
FibroGen reported a decline of 40.6% year-on-year quarterly revenue growth, falling to $116.07M over the past twelve months. Despite this setback, sales growth projected for current quarter was 16.6%; furthermore 138% was forecasted for subsequent quarter.
Potential Investment Opportunity and Forecast
Given FibroGen’s sharp drop in share value, those looking for undervalued stocks may find FibroGen intriguing as an undervalued investment opportunity. Yet its recent performance – particularly negative return on equity – suggests some financial instability; yet proposed sales growth over the next quarters may provide hope of recovery, making this development worthy of close observation and careful due diligence before jumping in with both feet.
More news about FibroGen (FGEN).
